<DOC>
	<DOCNO>NCT00971334</DOCNO>
	<brief_summary>The purpose study collect sample purpose develop prenatal aneuploid test use circulate cell free fetal ( ccff ) nucleic acid blood sample pregnant woman high-risk pregnancy undergo invasive prenatal diagnosis chorionic villus sampling ( CVS ) and/or genetic amniocentesis . The result ccff aneuploid test compare chromosomal analysis obtain via CVS amniocentesis .</brief_summary>
	<brief_title>Noninvasive Screening Fetal Aneuploidy : A New Maternal Plasma Marker</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Down Syndrome</mesh_term>
	<mesh_term>Aneuploidy</mesh_term>
	<criteria>Subject female Subject pregnant Subject 18 year age old Subject provide sign date informed consent Subject agree provide 3050mL blood sample Subject increase risk Down syndrome aneuploidy ( great equal 35 year age time delivery , elevate risk maternal serum marker include Triple , Quad integrate test , fetal birth defect marker identify ultrasound family history aneuploidy ) . Subject plan undergo amniocentesis and/or CVS procedure Subject agree FISH , karyotype , and/or QFPCR result obtain via invasive procedure provide</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Down Syndrome</keyword>
	<keyword>Aneuploidy</keyword>
	<keyword>Amniocentesis</keyword>
	<keyword>CVS</keyword>
</DOC>